The study involved blood samples from 30 people who had recovered from COVID-19 before the variants emerged. Researchers found CD8+ T-cells, which play a role in the body’s immune response to the virus, were able to recognize the B.1.1.7 variant, which first emerged in the U.K., the B.1.351 variant, first detected in South Africa and the B1.1.248 variant, first seen in Brazil.
“Researchers determined that SARS-CoV-2 specific CD8 + T-cell responses remained largely intact and could recognize virtually all mutations in the variants studied,” the NIH said in a news release. “While larger studies are needed, the researchers note that their findings suggest the T-cell response in convalescent individuals, and most likely in vaccines, are largely not affected by the mutations found in these variants, and should offer protection against emerging variants.”
Strong immunity likely involves both T-cell responses and neutralizing antibodies, the researchers said, adding that similar, larger studies are necessary to determine whether booster vaccinations are needed.
To view the full study, click here.
More articles on public health:
New variants could evade COVID-19 shot within a year, many epidemiologists say
Wisconsin Supreme Court overturns mask mandate
26$ of US COVID-19 cases traced to UK variant, CDC director says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
